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Fragment-based ligand design (FBLD) approaches
have become more widely used in drug discovery
projects from both academia and industry, and are
even often preferred to traditional high-throughput
screening (HTS) of large collection of compounds
(>105). A key advantage of FBLD approaches is that
these often rely on robust biophysical methods
such as NMR spectroscopy for detection of ligand
binding, hence are less prone to artifacts that too
often plague the results from HTS campaigns. In
this article, we introduce a screening strategy that
takes advantage of both the robustness of protein
NMR spectroscopy as the detection method, and
the basic principles of combinatorial chemistry to
enable the screening of large libraries of fragments
(>105 compounds) preassembled on a common
backbone. We used the method to identify com-
pounds that target protein-protein interactions.
INTRODUCTION
In recent years, fragment-based ligand discovery (FBLD)
approaches, also known as fragment-based drug discovery
(FBDD), have become popular alternative strategies to conven-
tional high-throughput screening (HTS) campaigns in both
academic and industrial drug discovery projects (Congreve
et al., 2008; Fischer and Hubbard, 2009; Hajduk and Greer,
2007; Murray and Rees, 2009). The basic idea behind FBDD
approaches is to initially identify, usually by screening small
focused libraries of low molecular weight compounds (frag-
ments) via biophysical methods, key chemical substructures or
pharmacophores sufficient to confer a minimal yet specific inter-
action with the given target. Subsequently, these fragment hits
arematured intomore potent binders by a variety of approaches,
most often guided by structural studies using X-ray crystallog-
raphy or nuclearmagnetic resonance (NMR) spectroscopy (Con-
greve et al., 2008; Dalvit, 2009; Hubbard, 2008;Murray and Blun-
dell, 2010; Pellecchia et al., 2002, 2004, 2008). Compared to HTS
libraries, fragments libraries contain lower molecular weight
compounds (MW < 300 Da), and the resulting hits are conse-
quently of weak binding affinity (with dissociation constants inChemistry & Biology 20,the micromolar to millimolar range). NMR spectroscopy has
been the most widely applied method in FBDD given its unique
advantages of (1) detecting fragment hits of weak binding affinity
(Kd values up to mM level) with little ambiguity (when spectra of
the target are obtained in the presence and absence of a test
compound), and (2) providing crude but insightful information
on the binding sites of hit compounds (Pellecchia et al., 2002,
2008). Binding information is usually obtained by using chemical
shift mapping techniques with 15N and/or uniformly or selectively
13C labeled protein, provided that resonance assignments for
the target and its three-dimensional structure are known.
Using protein-based NMR approaches, fragment libraries of
up to 10,000 compounds are routinely screened in a relatively
short time (from several hours to several days). Compounds
are usually tested in mixtures of 10–20, but higher throughput
is unlikely to be possible given the limitations of sample con-
sumption and the relatively long measurement times required.
Hence, HTS libraries, which usually contain more than 105 com-
pounds, cannot be screened by using NMR or other biophysical
approaches, as these methods have a limited throughput.
Generally, plate-based spectrophotometric assays are used in
HTS. Unfortunately, these methods often select for hundreds
or even thousands of misleading compounds, including nonspe-
cific hits, promiscuous aggregators, or other assay-related
artifacts, that render follow-up optimizations time-consuming,
tedious, and often unproductive and unsuccessful (Bo¨cker
et al., 2011; Feng et al., 2005, 2007; Shoichet, 2006a, 2006b).
Regardless of a large number of false hits, HTS has the advan-
tage of testing large libraries rapidly. On the other hand, FBDD
has the advantage of using a biophysical/analytical method,
such as NMR spectroscopy, to detect binding. These methods
are less prone to false hits, but can only be applied to test small
libraries, leading to fairly weak binding hits as starting points. As
a consequence, maturing the initial hits or linking multiple frag-
ments together into a more potent hit is necessary to obtain
a compound with sufficient potency to be used in subsequent
hit-to-lead optimizations. Maturing the fragments or linking
multiple fragments into a more potent binder is not a trivial task
and presents several challenges.
Here, we sought to combine the advantages of both
approaches in a screening strategy that we named HTS by
NMR. The approach combines basic combinatorial chemistry
principles with the advantages of using NMR spectroscopy as
the screening method, to screen larger libraries of compound
fragments that are preassembled on a common backbone. In19–33, January 24, 2013 ª2013 Elsevier Ltd All rights reserved 19
Figure 1. Schematic Representation of the HTS by NMR Approach
(A) First, a positional scanning library of compounds needs to be assembled. In
the example, a three-positions synthetic combinatorial library is prepared.
With a library of n fragments, there will be 33 nmixtures, each containing n3 n
compounds. Hence, rather than synthesizing and testing n 3 n 3 n individual
compounds, the approach would result in testing 33 nmixtures. For example,
a library of 100 fragments assembled at three different positions could be
sampled by screening 300 mixtures (100 + 100 + 100), rather than by syn-
thesizing and testing 1,000,000 (100 3 100 3 100) individual compounds.
(B) Chemical shift perturbations induced by each mixture are measured and
reported as function of the fixed fragment at each position.
(C) Based on a determined Dd cutoff, preferential fragments for each position
are selected and final individual compounds are synthesized.
(D) The binding affinity of the synthesized compounds is then determined via
2D heteronuclear NMR titration experiments.
See also Tables S1 and S2 reporting the composition of libraries used in the
manuscript for the method.
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making the method amenable to NMR-based screening tech-
niques, the library is assembled in mixtures in which each posi-20 Chemistry & Biology 20, 19–33, January 24, 2013 ª2013 Elseviertion of a common backbone is systematically fixed while the
other positions are populated by all possible functionalities,
a technique termed ‘‘positional scanning’’ (Dooley and
Houghten, 1993; Dooley et al., 1998; Houghten et al., 1991;
Pinilla et al., 1992). For example, a given library with a common
backbone that has three positions of diversity wherein each of
those diversity positions could be 1 of 100 functionalities (i.e.,
fragments) and could include up to 106 molecules (100 3
100 3 100) to be synthesized and tested. However, if prepared
in positional scanning mixtures, those fragments could be ar-
ranged and tested systematically using 100 + 100 + 100
mixtures. Hence, only 300 samples are needed to evaluate 106
compounds, and a sample set of 300 is highly amenable for
screening by NMR in a relatively short time (Figure 1). Obviously,
mixtures populated with the most effective fragment at a given
position would produce the largest signal changes in the NMR
spectra of the target, thus allowing the indirect identification of
the preferred combinations of scaffolds (Figure 1). Subsequent
synthesis and testing of individual compounds would result in
the identification of the most active compounds among the
possible 106 molecules (Figure 1). Because the final individual
scaffolds identified by the approach are already arranged and
linked in a specific order, these hits are immediately amenable
to subsequent empirical medicinal chemistry strategies for hit-
to-lead optimizations backed up by robust NMR-based binding
data—without concern about artifact data and without the need
to determine the structure of the complex to guide fragment link-
ing or growing. Moreover, because NMR is an unbiased
screening technique, ligands for different areas of the protein
surface could be identified simultaneously, possibly delineating
a protein’s hot spots or allosteric sites that were not known
previously.
As an initial proof-of-concept application, we explored
experimental conditions for the HTS by NMR approach and
examined its feasibility by targeting the baculovirus inhibitor of
apoptosis protein (IAP) repeat 3 (BIR3) domain of the antiapop-
totic protein XIAP, which is known to bind the high-affinity tetra-
peptide ligand AVPF (Fesik and Shi, 2001; Sharma et al., 2006).
In addition, we further applied the HTS by NMR in a de novo
ligand discovery program against the ligand-binding domain
(LBD) of the EphA4 receptor tyrosine kinase. Our data demon-
strate the feasibility of the approach, and furthermore suggest
that the method may be more successful than conventional
HTS campaign in designing effective inhibitors of protein-protein
interactions (PPI).
RESULTS AND DISCUSSION
HTS by NMR: Approach and Proof of Concept
As mentioned above, the main concept of the HTS by NMR is to
identify fragment hits that are already preassembled on a
common scaffold or backbone, so that the resulting hits would
have the characteristics of HTS compounds but also the verified
ability to specifically interact with the target provided by the
NMR-based screening data. The general strategy is depicted
schematically in Figure 1. In order to perform the HTS by NMR,
a positional scanning synthetic combinatorial library is first
designed in which each mixture is composed of thousands to
millions of compounds, all of which have one position fixed byLtd All rights reserved
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positions are diversified by all fragment components (Figure 1A).
Binding of the mixtures to a protein target is subsequently de-
tected via protein-based NMR chemical-shift perturbation
experiments. The chemical shift of a given nucleus represents
its local environment, which can be perturbed upon the binding
of a compound in its proximity, causing the corresponding
signals in the protein spectrum to change in position. If the
binding falls into a fast exchange on the chemical-shift time
scale, which is generally the case for binders with dissociation
constants in the millimolar to nanomolar range, then the ob-
served chemical shifts are the weight average of the signals of
the protein in the free and bound states as shown in Equation 2
in Experimental Procedures (Pellecchia, 2005; Smet et al., 2005).
Compared with the protein concentration in the NMR sample
(usually between 5 and 100 mM), each compound in the mixture
has a concentration that could practically reach only nanomolar
or lower concentrations, depending on the number of fragments
and positions scanned. Hence, one apparent challenge for the
success of the HTS by NMR approach is whether NMR is sensi-
tive enough to detect binding of compounds in such mixture-
based samples under these experimental conditions. It is
obvious that if the concentration of binding compounds is too
low, compared to the protein concentration and the dissociation
constant, then chemical shift differentials between the free and
bound states are small and difficult to detect. However, if even
low percentages of compounds in a mixture bind to the protein,
then the large number of compounds containing a ‘‘hit’’ fragment
at a given position collectively may contribute to produce
observable and unambiguous perturbations in the NMR spectra
of the target. Given the dominating concentration of the fixed
fragment in a mixture, we hypothesize that the fixed fragment
is the main contributor to the observed chemical shift perturba-
tions. Therefore, each fixed fragment could be evaluated based
on the resulting chemical shift perturbations in the various
mixtures (Figure 1B). In theory, the most potent compound can
be deduced from the combination of the mixtures producing
the highest chemical shift perturbations at each position,
assuming that a given scaffold adopts the same binding mode
when present in different compounds. This is not necessarily
true because compounds could, in principle, bind in different
orientations. For example, if P1 is a binder for the target, either
the mixture P1-X-X or the mixture X-X-P1 could position the P1
fragment at the same subpocket within the protein surface,
and that would produce the erroneous suggestion to synthesize
a P1-X-P1 series. Although this phenomenon could produce
inactive combinations, the chance of this to occur diminishes
with the complexity of the fragments. For example, if the X-X
fragments in the P1-X-X or X-X-P1 examples are mere linkers
or small fragments (let’s say a Gly-Gly linker, for example), the
P1 could likely more freely occupy the same subpocket while
embedded in either the P1-X-X or the X-X-P1 molecules.
However, when, as in our case, the X-X are more complex and
functionalized side chains, the probability of P1 being free to
find the same subpocket regardless of its position, while still
possible, it is diminished by steric contacts that other adjacent
side chains can create. On balance, to find the most potent
compounds, it is best to choose different fragment combinations
(Figure 1C), synthesize them, and subsequently test the resultingChemistry & Biology 20,individual compounds experimentally by means of two-dimen-
sional (2D) heteronuclear NMR titrations (Figure 1D).
The scanning approach has been extensively used and vali-
dated in the identification of antigen-specific and protease-
specific synthetic peptides from screening of large positional
scanned libraries (Judkowski et al., 2011; Lim and Craik, 2009;
Lustgarten et al., 2006; Pinilla et al., 1999; Reddy et al., 2011; So-
spedra et al., 2010). However, unlike these previous positional
scanning assay studies, which depend mostly on either fluores-
cence or absorbance readouts (Diamond, 2007; Lim and Craik,
2009), using protein-based NMR to perform positional scanning
does not require specific knowledge of protein function for assay
establishment. Moreover, the HTS by NMR approach not only
identifies preferred scaffolds and initial hit compounds, but
also determines their binding affinity and, in most cases, the
site of binding, allowing formore direct follow-up hit-to-lead opti-
mizations. In fact, protein-based NMR chemical shift perturba-
tion can be used not only as a screening technique, but also to
map compound binding sites on a protein structure when
combined with resonance assignments, therefore providing
initial structural information for future hit optimizations. More-
over, asmentioned, compound aggregators, redox, or otherwise
reactive small molecules cause false hits that plague screening
results from most spectrophotometric assay platforms (Baell
and Holloway, 2010; Shoichet, 2006a, 2006b) and even other
biophysical screening techniques such as surface plasmon reso-
nance (Giannetti et al., 2008). However, because NMR is
a powerful analytical technique to assess the integrity of the
protein target, compounds (or mixtures in the primary screens)
that cause aggregation or protein denaturation are readily iden-
tified and eliminated. Of note is that of the tested mixtures, only
one seemed to cause aggregation of the LBD of EphA4 under the
experimental conditions used. Again, these ‘‘aggregators’’ are
readily identified, and hence not considered as hits.
Application of the HTS by NMR against the Bir3 Domain
of XIAP as Proof of Concept
To assess the feasibility of the HTS by NMR approach, we
applied it on a test case in which a target protein and its binders
have been well studied. The target protein chosen in the training
set is the BIR3 domain of the antiapoptotic protein XIAP, which
binds directly to the N terminus of caspase-9 to inhibit pro-
grammed cell death (Fesik and Shi, 2001; Shiozaki et al., 2003;
Wang et al., 2004). It has been shown that in the cell, this interac-
tion can be displaced by the protein SMAC (second mitochon-
drial activator of caspases) and that the N-terminal tetrapeptide
region (AVPF) of SMAC is responsible for the binding (Shiozaki
et al., 2003; Srinivasula et al., 2001). Previous studies have
also indicated that Ala and Pro are absolutely conserved at the
positions P1 and P3 (from the N terminus) in the consensus
AVPF motif, which is sufficient for binding to BIR3. Modifications
of this AVPF motif have recently led to the generation of
numerous XIAP antagonists as anticancer agents, some of which
are currently under clinical investigation (Bank et al., 2008;
Flygare and Fairbrother, 2010; Li et al., 2004). To evaluate
whether the contribution of Ala and Pro to the binding could
have been detected via HTS by NMR, we selected mixtures
from combinatorial libraries of synthetic peptides of different
lengths (Table S1 available online), including peptide mixtures19–33, January 24, 2013 ª2013 Elsevier Ltd All rights reserved 21
Figure 2. Application of the HTS by NMR to
the BIR3 Domain of XIAP
Superposition of 2D [15N, 1H]-HSQC spectra of
BIR3 domain if XIAP, measured in the absence
and presence of the mixtures from a hexapeptide
positional scanning library. The spectrum for apo-
BIR3 is colored in red. The spectrum for BIR3 in
the presence of AXXXXX is colored in green, in the
presence of XXPXXX is colored in orange, in the
presence of GXXXXX is colored in cyan and in
the presence of the control peptide AVPFGYSA
YPDSVPMMSK is colored in blue. X represents
a possible fragment, whereas A, P, and G repre-
sent alanine, proline, and glycine, respectively.
The new occurring peaks with the addition of
control peptide, the AXXXXX mixture, and the
XXPXXX mixture, are circled in black.
See also Figure S1 and Table S1.
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at the P3 position. As controls, different mixtures with Gly fixed
at P1 were also tested in the training set. Regardless of the
diverse components and number of compounds included (Table
S1), nine different mixtures were dissolved in DMSO as stock
solutions with the overall concentration of a given mixture close
to 150 mM relative to the fixed position.
To detect the binding of the mixtures, we collected a series of
2D [15N, 1H] heteronuclear single quantum correlation (HSQC)
spectra of 50 mM 15N-labeled BIR3 in the absence and presence
of 1 mM mixtures. Assuming a hit rate as low as 1%, the overall
concentration of a binding fragment at a fixed position would
reach 10 mM, which is comparable to the 50 mM concentration
of BIR3, thus possibly generating significant chemical shift
perturbations. As shown in Figures 2A and 2B, the overall
HSQC spectra of BIR3 experienced significant changes with
the addition of the AXXXXX and XXPXXX mixtures, especially in
the appearance of a few additional peaks. The same changes
were also observed with the addition of the control peptide
(AVPFGYSAYPDSVPMMSK), which contains a consensus
AVPF motif at the N terminus (Figure 2D). It has been reported
that these new occurring peaks around 122–127 ppm (15N) and
8–9 ppm (1HN) result from residues in the flexible loop nearby
the BIR3 binding pocket once its conformation is stabilized by
the bound peptide (de Souza et al., 2010; Moore et al., 2009).
Therefore, the chemical shift perturbation data indicated that
AXXXXX and XXPXXX mixtures contain ligands that interact
with BIR3 in a way that is similar to the binding of the known
AVPF motif. When the fixed residue Ala is replaced by Gly at
P1, however, only minor chemical shift perturbations were
observed and the new occurring peaks mentioned above did
not appear (Figure 2C). Hence, significantly different binding
behavior of AXXXXX and GXXXXX indicates that the Ala residue22 Chemistry & Biology 20, 19–33, January 24, 2013 ª2013 Elsevier Ltd All rights reservedat position P1 is critical for binding to
BIR3. This is in agreement with well-
documented studies with AVPF and
related small molecule inhibitors currently
in the clinic, all containing an Ala or an Ala
mimetic at the P1 position. Similarly, the
tetrapeptide mixtures AXXX and XXPXcaused significant chemical shift perturbations, while GXXX
showed no significant binding (Figure S1), under the same exper-
imental conditions. The shorter tripeptidemixtures AXX and XXP,
however, only caused smaller shifts, presumably due to the lack
of the fourth consensus amino acid (Figure S1). The above
results are in agreement with the previous conclusion that Ala
and Pro are important for binding to BIR3 when peptides are
four residues or longer (Sharma et al., 2006). These proof-
of-concept results clearly indicate that the HTS by NMR is an
effective approach to identify critical ‘‘fragments’’ in complex
mixtures of hundreds of thousands compounds even if the
individual concentration of each compound is relatively low. Ex-
panding on this approach to small-molecule-like libraries or
peptide-mimetic libraries holds great promise as a novel method
for hit generation, as next example will demonstrate.
Application of the HTS by NMR Approach for De Novo
Ligand Identification
To test the applicability of the HTS by NMR approach to de novo
ligand identification, we used it with the EphA4 LBD. EphA4
belongs to the Eph family of receptor tyrosine kinases, which
together with their membrane-bound ligands, the ephrins (Eph
receptor-interacting proteins), generate bidirectional signals
controlling a multitude of cellular processes during development
and in the adult (Pasquale, 2005, 2008, 2010). The critical roles of
EphA4 in various physiological and pathological processes have
been reported in previous studies validating EphA4 as a prom-
ising target for the development of small molecule drugs to treat
human diseases, such as abnormal blood clotting, spinal cord
injury, amyotrophic lateral sclerosis, and certain types of cancer
(Noberini et al., 2008, 2011a, 2011b; Qin et al., 2008, 2010).
Previous structural studies indicate that the EphA4 LBD
contains a hydrophobic pocket surrounded by four flexible loops
Figure 3. Pretesting of the Mixture Library by NMR
(A) Superposition of 2D 15N-HSQC spectra of EphA4 LBD in the absence (red)
and presence (green) of the prescreening mixture XXX. The binding site
resonances shifting upon exposing the protein to the mixture are labeled by
arrows or a circle.
(B) 1D 1H aliphatic spectra of 5 mM EphA4 LBD in the apo form (black) and in
the presence of 2 mM XXX (blue) and 4 mM XXX (red). The region of the
spectrum affected by the presence of the mixture XXX is labeled by an arrow.
See also Table S2.
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structural plasticity to accommodate different binding partners
(Bowden et al., 2009). Several 12-amino-acid-long peptide
binders that selectively block ephrin ligands from binding to
EphA4 have been reported (Murai et al., 2003). For instance,
the APY, KYL, and VTM peptides (which were named based
on the first three amino acids of their sequences) bind to
EphA4 tightly with Kd values in the low micromolar range (Lam-
berto et al., 2012; Murai et al., 2003). In addition, a few small
molecular weight compounds that inhibit ephrin binding to
EphA4 at lowmicromolar concentration have also been reported
from HTS campaigns (Giorgio et al., 2011; Noberini et al., 2008,
2011a, 2011b; Qin et al., 2008). However, their detailed mecha-
nism of action remains unclear and likely complex, possibly
involving compound oxidations or covalent binding, which are
typical issues encountered in traditional HTS hits (Baell and Hol-
loway, 2010; Noberini et al., 2008, 2011a, 2011b).
In this study, we screened a positional scanning library made
up of the combinations of 58 amino acids at each position. In
order to increase the drug likeness and the diversity of the
compounds in the library, in addition to the natural L-amino-
acids, we also included several nonnatural amino acids (TableChemistry & Biology 20,S2). These 58 amino acids led to increased position diversity
while producing average molecular weights of compounds in
each mixture of about 500 Da or less (Table S2). Hence, a total
of 174mixtures (58 + 58 + 58) were obtained, each of which con-
tained 3,364 compounds (1 3 58 3 58), with one fixed position
and two positions where all combinations of the different 58
amino acids are incorporated.
Because screening compound libraries by NMR can be time
and material intensive, we also sought to develop a simple
strategy to prescreen a chosen library against a target in order
to quickly evaluate the probability of finding hits using this
approach. Hence, we prepared a single sample containing the
entire collection, in which all three positions contain all amino
acids (58 3 58 3 58 compounds). Therefore, the sample used
in the prescreening procedure includes all the combinations of
the fragments in the screening library. The idea behind the pre-
screening is that if multiple compounds binding to the target
protein exist in the screening library, then detectable chemical
shift perturbations should take place because various binders
would cumulatively contribute to these shifts. Obviously, the pre-
screening has critical requirements for protein and compound
mixture concentrations. This type of prescreening has been re-
ported to be successful for other assays, including in vivo
models, and it has been termed ‘‘scaffold ranking’’ (Houghten
et al., 2008; Ranjit et al., 2010; Reilley et al., 2010; Rideout
et al., 2011).
The mixture used in the prescreening contained in theory all
195,112 possible compounds in the screening library. The capa-
bility of such XXXmixture components to interact with the EphA4
LBD was determined by comparing the cross peak changes on
the 2D [15N, 1H]-HSQC spectra of 15N-labeled EphA4 LBD at
5 mM concentration in the absence and presence of the mixture
at 4 mM. In such conditions, and with a typical high-field NMR
instrument (600–800MHzwith cryogenic probes), protein-based
NMR spectra are collected within several hours, depending on
the protein molecular weight, the experimental setup, and the
observed nuclei (1H, 15N, 13C). As shown in Figure 3A, addition
of the XXX mixture to a sample of 15N-labeled EphA4 LBD
caused chemical shift perturbations that are similar to those
caused by known inhibitors, inducing changes that are more
noticeable in the side chain of residue Gln43 and other residues
(Qin et al., 2008). Hence, the simple prescreening assay indi-
cated the existence of binding compounds in the screening
library, providing the motivation for performing the complete
screen of the individual positional scanned mixtures to identify
them. Because of the unbiased nature of the NMR-based
screen, we propose that such a prescreening approach is suit-
able for assessing the druggability of novel targets and/or to
identify novel binding surfaces on known targets.
To increase the throughput of the NMR-based screen and to
reduce the amount of protein needed, we also monitored the
aliphatic region (at 1 ppm and below) of the EphA4 LBD target
in simple one-dimensional (1D) 1H-NMR spectra. This region
contains resonances from the methyl groups of protein residues
and it is rarely populated by signals from organic molecules,
which conveniently allows it to be used as an effective primary
screening tool to detect compound binding (Stebbins et al.,
2007). As shown in Figure 3B, the 1D 1H-aliphatic-NMR spec-
trum of the EphA4 LBD presented a well separated region that19–33, January 24, 2013 ª2013 Elsevier Ltd All rights reserved 23
Figure 4. Application of the HTS by NMR in
the Identification of Ligands against EphA4
LBD
(A) Score matrix illustrating the results from the
HTS by NMR with the EphA4 LBD. The chemical
shift changes on the monitored peak are plotted
versus the fixed fragment numbers on different
positions in which P-1 is colored in gray, P-2 is
colored in red, and P-3 is colored in green. The
fragments with the highest induced chemical shift
perturbation at each position aswell as the second
highest induced chemical shift perturbation at P-2
were labeled in bracket.
(B) Structures of compounds 1 to 5. The combi-
nation of the fragments with the highest score at
each position resulted in compound 1. The com-
bination of the fragments with the highest score at
P-1 and P-3, and the second highest score at P-2,
resulted in compound 2.
See also Figures S2, S3, and S8 and Tables S2
and S3.
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in buffer conditions, making the identification of potential
compounds straightforward and unambiguous. Hence, 1D 1H-
aliphatic-NMR measurements were performed by using a 5 mM
protein sample and the XXX prescreening mixture at two
different concentrations (2 and 4 mM total concentration). Under
these conditions, a new signal gradually shifted out of the over-
lapped peaks at 0.2 ppm, indicating binding events taking
place upon titration of the mixture (Figure 3B). Because collect-
ing 1D 1H spectra generally requires significantly less protein and
relatively shorter measurement times (typically from a few
minutes to a few hours, depending on the spectrometer used
and the protein’s molecular weight) than typical 2D [15N,1H]-
HSQC and/or [13C,1H]-HMQC spectra, we believe this approach
can extend significantly the use of NMR for screening larger
libraries of compounds. Hence, we named the overall method
‘‘HTS by NMR.’’
Based on these results, we next performed a screen of the full
library by collecting a series of 1D 1H-aliphatic-NMR spectra of
5 mM EphA4 in the presence of each of the 174 mixtures
comprising the tripeptide positional scanning library at an overall
concentration of 1 mM each (0.3 mM for each compound in
a mixture). To roughly evaluate and rank order the binding
preference of fragments in the mixtures, chemical shift perturba-
tions for each position were measured and summarized in24 Chemistry & Biology 20, 19–33, January 24, 2013 ª2013 Elsevier Ltd All rights reserveda score matrix (Figure 4A). Each position
was then analyzed separately, resulting
in the selection of fragments 45 and 32
for the P-1 position, fragments 16, 47,
51, and 53 for the P-2 position, and
fragment 51 for the P-3 position. The indi-
vidual compounds with various fragment
combinations (Figure 4) were subse-
quently synthesized and tested for
binding byNMR and subsequently further
characterized and validated by other
biophysical and biochemical means (see
below). To validate the binding of thesynthesized compounds, a series of 2D [15N, 1H]-HSQC spectra
of 50 mM EphA4 LBD in the absence and presence of 100 mM of
the individual compoundswere collected. The resulting chemical
shift differences for the binding compounds were quantified as
described in Experimental Procedures, and the shifts induced
on the backbone amide of residue T76 located at the bottom
of the binding pocket were used to roughly rank order the
compounds and estimate the binding affinity of each compound
for the receptor.
Compound 1 (Figure 4B) is the molecule carrying the frag-
ments that induced the largest Dd perturbations in the mixtures.
Compound 1 caused small but significant chemical shift pertur-
bations under these conditions (Figure S2), implying that it
possesses moderate affinity for the EphA4 LBD compared to
the other initial compounds tested. The dissociation constant
(Kd) value of compound 1 binding to the EphA4 LBD was
calculated to be 227 mMvia NMR titration experiments, conduct-
ed by tracing the chemical shifts for the backbone 1HN/15N nuclei
of residue T76 in the 2D [15N, 1H]-HSQC spectra of EphA4 LBD
(data not shown). Mapping the chemical shift changes along
the primary sequence and the three-dimensional structure of
the EphA4 LBD indicated that compound 1 targets its ligand-
binding pocket (Figure S2). When fragment 45 on P-1 in
compound 1 is replaced by fragment 32 (compound 2; Fig-
ure 4B), however, no significant binding is observed. This
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scores at each position does not always and necessarily yield
a potent compound, as explained earlier, likely due to different
binding orientations of the fragments when embedded in
different molecules. Nonetheless, the method is significant as
long as at the least one reasonably potent hit is found.
In view of the importance of fragment 45 at P-1 position and
the larger chemical shift perturbations caused by fragment 51
at P-3, the effects of P-2 diversity on binding to the EphA4
LBD were evaluated in compounds 3–6, all of which are analogs
of compound 1. Compound 6 possesses the strongest binding
affinity for the EphA4 LBD (Table 1), inducing significant changes
in its 2D [15N, 1H]-HSQC spectra (Figure 5A). Interestingly,
different from compound 1, which exhibits a characteristic
‘‘peak walking’’ upon titration, typical of a fast exchange binding
pattern (Figure 5B), upon titrating compound 6 into EphA4, the
peaks corresponding to residues in the binding site residues
loosed intensity at low ligand concentration and then gradually
reappeared at different chemical shifts during the titration (Fig-
ure 5B). This is a typical intermediate exchange pattern on the
chemical shift time scale for protein-ligand interactions, which
usually suggests stronger binding affinities (dissociation con-
stants approaching the low micromolar range). Mapping the
most perturbed residues on the surface of EphA4 LBD indicated
that two residues experiencing intermediate exchange upon
binding are located at the bottom of the ephrin binding pocket
while the other perturbed residues are located in a subpocket
formed by the nearby DE and GH loops (Figures 5C and 5D).
Given the plasticity of these loops as well as the flexibility of
the backbone of compound 6, a conformational rearrangement
around the pocket might occur during the binding of compound
6, which may also account for the observed slow exchange
behavior in the titration.
When a protein-ligand interaction falls in slow or intermediate
exchange on the NMR time scale, integrating cross peaks on 2D
[15N, 1H]-HSQC spectra is required to calculate the molar frac-
tion of nuclei in the free and bound states. This is generally
difficult, which limits the application of NMR titration as
a method for accurately measure dissociation constants. To
circumvent this limitation, we applied an additional method
based on fluorescence polarization to compare the binding
potencies of the synthesized compounds. The fluorescence
polarization assay (FPA) measures changes in the polarization
of the light that results from a free tumbling fluoresceinated
reference molecule and the same molecule in complex with
a larger protein, which slows its rotational correlation times in
solution (Jameson and Sawyer, 1995; Nasir and Jolley, 1999;
Stewart et al., 2010). To study the interactions between the
compounds and EphA4, 5 mM FITC-labeled control KYL peptide
(KYLPYWPVLSSL) was incubated with 2 mM EphA4 LBD. After
a 30 min incubation, the compounds were added, causing the
release of the bound FITC-KYL molecules and a decrease in
fluorescence polarization. By fitting the polarization changes
at the various concentrations of the compounds, IC50 values
can be estimated. The FPA measurements indicated that
compound 6 possesses a stronger EphA4 binding potency
than compound 1, consistent with what we observed in the
NMR titration experiments. As a comparison, the IC50 value of
unlabeled KYL peptide was also determined (Table 1). TakenChemistry & Biology 20,together, these results indicate that compounds 1 and 6 target
the ligand-binding pocket of EphA4.
Interestingly, we tested if individual side chains of compound
6, namely 3-methylindole and 4-chlorotoluene occupying posi-
tions P-2 and P-3, respectively, bind to the EphA4 LBD. Upon
titration, these fragments caused small chemical shift perturba-
tions in the 2D [15N, 1H]-HSQC spectra of EphA4 LBD, but these
were observable at only higher ligand concentrations (3 mM),
suggesting weak binding affinities against the protein (Figures
S3 and S8). Chemical shift mapping indicated that the 3-methyl-
indole mainly affected residues on the side of the pocket
composed of loops BC and DE (Figure S8). On the contrary,
the 4-chlorotoluene produced largest chemical shift perturba-
tions (Dppm above 0.03 ppm) that localized in a nearby sub-
pocket composed of loops GH and JK (Figure S8). These data
suggest that the two fragments indeed occupy adjacent
subpockets.
In addition of testing these side chains individually, we also
tested the binding of compounds with the common scaffold
carrying only one fragment at one position and two Gly residues
at the two other positions (i.e., G-16-G and G-G-51). Again,
binding of these test molecules can be observed only at milli-
molar ligand concentrations, with only minor shifts observed
(Figure S3).
These binding studies revealed two points: first, the individual
fragments exhibit weak binding affinities for the target protein,
which is difficult to detect; second, incorporating a given
fragment hit into the library, as in our approach, allows its
unambiguous detection even at lower concentrations. These
results support our hypothesis that preloading the fragments
on a common backbone, arranged in positional scanning
mixtures libraries, provides an effective mean for hit identifica-
tion via NMR.
Similar to other fragment-based techniques, such as the SAR
by NMR (Shuker et al., 1996), the approach is unbiased toward
a particular pocket and does not require preconceived assays.
However, unlike other fragment-based approaches, no struc-
tural characterization of the fragment’s target complex and/or
systematic linker optimizations is necessary to obtain initial hit
compounds.
Hit-to-Lead Optimizations
To further enhance the binding potency of the compounds,
compound 6 was subsequently used as a starting point for
iterative optimizations, mainly by incorporating additional
heavy atoms and selecting fragment analogs to investigate
the structure-activity relationships (SAR) of the compounds.
First, four analogs of compound 6, namely compounds 7–10,
were synthesized by elongating compound 6 at position P-4
with either a Lys, Glu, Phe, or Val amino acid, as representa-
tives of four different residue types (positively charged, nega-
tively charged, aromatic, and aliphatic, respectively). Because
the compounds were first identified, and hence validated, by
NMR, at this hit-to-lead optimization stage we can use the
FPA and/or ELISA to more rapidly monitor progress, although
NMR and/or isothermal titration calorimetry (ITC) validations
could be conducted in parallel, and must be conducted at
the least on key compounds. FPA studies revealed that, except
for compound 8 with Glu on position P-4, compounds 7, 9, and
10 all exhibited significant improvements over compound 6,19–33, January 24, 2013 ª2013 Elsevier Ltd All rights reserved 25
Table 1. Structure-Activity Relationship Studies for the Reported EphA4 LBD Ligands
Hit structure at each 
modification stage Name M.W.
R1  in defined 
position
IC50
by FPA 
(µM)*
Kd
by ITC
(µM)
6 455 -NH2 388 ± 30 -
7 584 L-lysine-NH2 206 ± 27 -
8 585 L-glutamate-NH2 398 ± 75 -
9 603 L-phenylalanine-NH2 273 ± 117 41 
10 555 L-valine-NH2 262 ± 75 -
11 618 L-4-methylphenylalanine-NH2
- -
12 605 L-4-pyridylalanine-NH2 100 ± 32 20 
13 637 L-4-chlorophenylalanine-NH2
ND ND
14 622 L-4-fluorophenylalanine-NH2
99 ± 34 -
15 620 24 ± 6.2 12
16 635 29 ± 6.4 14.9
17 622 73 ± 36 -
18 622 54 ± 23 -
19 619 118 ± 67 -
(Continued on next page)
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Table 1. Continued
See also Figures S4–S6 and Table S4.
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1D 1H spectra of EphA4 to validate their binding, we noticed
that only compound 9 with Phe on P-4 caused shifts in the
intermediate exchange on the monitored peak at 0.2 ppm
(data not shown), possibly suggesting a stronger binding
affinity of compound 9 compared to compounds 7 and 10.
Therefore, compound 9 was selected in this iteration for further
evolutions.
In a second iteration, four derivatives of compound 9
(compounds 11–14) with analogs of Phe at position P-4
were synthesized and SAR data were obtained by FPA andChemistry & Biology 20,ELISA. FPAs yielded IC50 values of about 100 mM for
compounds 12 and 14, which are approximately 2-fold better
than the initial hit compound 9 (Table 1). IC50 values could not
be obtained for compounds 11 and 13 due to their poor solu-
bility at concentrations above 200 mM; hence, these were no
longer considered. Additional ELISA competition assays re-
vealed that compounds 12 and 14 competed for the binding
of ephrin-A5 alkaline phosphatase (AP) to EphA4, with 75%
inhibition at 500 mM for compound 12 and 40% inhibition for
compound 14 (Figure 6A). Consistent with the results from
FPAs, ELISAs also indicated that compounds 11 and 1319–33, January 24, 2013 ª2013 Elsevier Ltd All rights reserved 27
Figure 5. Chemical Shift Mapping Studies
with Initial Hits against EphA4 LBD
(A) Superposition of 2D [15N,1H]-HSQC spectra for
50 mM EphA4 LBD in the absence (red) and pres-
ence (cyan) of 300 mM compound 6.
(B) Close-up view of the region boxed in (A)
showing an overlap of 2D [15N,1H]-HSQC spectra
for 50 mM EphA4 LBD in presence of various
concentration of compound 6 (top panel) or
compound 1 (bottom panel).
(C) Summary of the chemical shift perturbation
resulting from the binding of 300 mM compound 6
to the EphA4 LBD. The average chemical shift
changes of each residue were calculated based
on Equation 1 in Experimental Procedures.
(D) Chemical shift mapping for the binding of
compound 6 on the ribbon representation (left
panel) or surface representation (right panel) of the
EphA4 LBD. Residues with averaged Dd above 0.1
ppm are colored in red; residues experiencing
intermediate exchange are colored in purple. The
loops in the ribbon structure of the EphA4 LBD are
also labeled. The surface structure of the EphA4
LBD is from PDB code 3CKH; Swiss-Model 3D
was used to add the missing loops to the crystal
structure.
See also Figure S8.
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these experimental conditions. All the above results suggested
that compound 12 possesses higher affinity for the target
compared to compounds 11, 13, and 14. Therefore,
compound 12 was chosen as the hit compound for the next
iteration.
Because varying the fragments at position P-2 resulted in
compounds with improved affinities, we further derivatized the
indole ring at position P-2 of compound 12 with other analogs
(compounds 15–21; Table 1). Among seven synthesized mole-
cules, compounds 15 and 16 exhibited the most significant
improvement in displacing the reference peptide, with IC50
values of 24 and 29 mM, respectively (by FPA), which corre-
sponded to a 3- to 4-fold improvement compared to compound
12 (IC50 100 mM). The IC50 values for compounds 15 and 16
were also determined in dose-response ELISA measuring the
ability of the compounds to displace the natural ligand, ephrin-
A5, from EphA4. In this assay, we observed IC50 values of
170 mM for compound 12, 50 mM for compound 15, and 71 mM28 Chemistry & Biology 20, 19–33, January 24, 2013 ª2013 Elsevier Ltd All rights reservedfor compound 16 (Figure 6B and data
not shown). Thus, the three compounds
inhibited not only binding of the KYL
peptide to EphA4, but also the binding
of the natural ephrin ligand. Although the
IC50 values obtained by two methods
are slightly different, likely because of
the higher EphA4 binding affinity of
ephrin-A5 compared to the KYL peptide,
the same ranking is clearly observed
in that compounds 15 and 16 exhibit
more pronounced inhibition than com-
pound 12.Compounds 15 and 16 share some structural features with the
KYLPYWPVLSSL reference peptide, such as a positively
charged group on the first position (side chain of Lys in
KYLPYWPVLSSL versus N terminus of b-Ala in compound 15
and 16) and an aromatic ring on the second position (Tyr in
KYL versus Trp analogs in compounds 15 and 16). However, in
the KYLPYWPVLSSL peptide, there are several additional
hydrophobic residues in the central part of the sequence. Hence,
to further improve the binding potency of compound 15, we
incorporated an extra hydrophobic group on the C terminus of
compound 15 and synthesized compounds 22–30. Among
these compounds, compound 22 displayed a Kd value of
3.77 mM (by ITC, see below) and an IC50 value for inhibition of
EphA4-ephrin-A5 binding in ELISA of 3.4 mM (Figure 6B, see
below). These values are 10- to 20-fold lower than those
obtained with compounds 15 and 16 and comparable to the
12-mer KYLPYWPVLSSL peptide.
To further confirm the binding of compounds 12 and 15, 2D
[15N, 1H]-HSQC spectra of 50 mM 15N-labeled EphA4 LBD
Figure 6. Compounds Identified by the HTS by NMR Inhibit Ephrin Ligand Binding to EphA4 and Ephrin-Dependent EphA4 Tyrosine Phos-
phorylation in Cells
(A) Inhibition of ephrin-A5 AP binding to immobilized EphA receptor Fc fusion proteins and ephrin-B2 AP binding to immobilized EphB receptor Fc fusion proteins
in the presence of the peptides relative to no peptide. All the compounds were tested at 500 mM, with the exception of compound 22, which was tested at 15 mM.
Error bars represent the standard errors from two to four measurements.
(B) Inhibition of ephrin-A5 AP binding to immobilized EphA4 Fc by compounds 15, 16, and 22 and by the KYL peptide. Error bars represent the standard errors
from two to four measurements. R2 values indicating the goodness of fit for the inhibition curves were 0.97 for peptide 15, 0.95 for peptide 16, 0.93 for peptide 22
and 0.97 for KYL.
See also Figures S5–S7 and Table S4.
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compound were collected. After the addition of compounds
12, 15, or 22, significant chemical shift perturbations wereChemistry & Biology 20,observed and the perturbed residues were similar to those
affected by compound 6, consistent with targeting of the
ephrin-binding pocket of EphA4 (Figures S4 and S5). The19–33, January 24, 2013 ª2013 Elsevier Ltd All rights reserved 29
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were then determined via ITC (see also Figure S6 and Table
S3), which yielded Kd values of 20, 12, and 14.9 mM for
compounds 12, 15, and 16, respectively. In addition, the control
12-mer peptide KYLPYWPVLSSL was also tested by ITC, which
yielded a Kd of 1.3 mM under the same experimental conditions.
The parameters derived from the ITC experiments indicated that
the interaction between the binders (including KYLPYWPVLSSL
and the synthesized compounds) and EphA4 LBD is enthalpy
driven. Although the Kd values of compounds 15 and 16 are
weaker than the control KYLPYWPVLSSL peptide, compounds
15 and 16 exhibit significantly better ligand efficiencies (0.151
for compound 15 versus 0.086 for KYL) because of their smaller
molecular weight. Of note is that the tetrapeptide KYLP derived
from the KYLPYWPVLSSL sequence resulted inactive by NMR
and FPA under similar experimental conditions.
Moreover, together with the improved binding affinity, the
compound selectivity is also markedly improved. As shown in
Figure 6A, the first-generation compound 6 inhibited the binding
of ephrin-A5 AP to EphA4 by 45%at 500 mM, but also with some-
what lower potency other Eph receptors such as EphB2, EphB4,
andEphB6 (inhibitions between 15%and30%).Compound 9 ex-
hibited not only higher inhibition of EphA4-ephrin-A5 binding
(more than 50% at 500 mM), but also higher selectivity, and only
inhibited EphA2 by less than 15% besides EphA4. Compounds
15 and 16 exhibited even improved inhibition of ephrin binding
to EphA4 (around 90%) among the EphA and EphB receptors
examined, with some minor inhibition of EphA3 (25%) and no or
weak inhibition of other Eph receptors (less than 5%). This is
confirmed by NMR experiments showing that compound 15
caused significant chemical shift perturbations in EphA4 spectra
and only minor changes in EphA3 LBD spectra, while no signifi-
cant perturbations were detected in the EphA2 LBD spectra
under the same experimental conditions (data not shown).
In addition to having improved potency, compound 22 showed
high selectivity for EphA4 as at 15 mM it inhibited only EphA4
among the receptors tested (Figure 6). Compounds 15, 16, and
22 also appear to be remarkably resistant to proteases present
in biological fluids, as assessed by measuring the ability of the
compounds to inhibit EphA4-ephrin-A5 interaction in ELISAs
after incubation in cell culture medium or mouse serum (Fig-
ure S7). In these stability assays, compound 15 had a half-life
of 12 hr in mouse serum, while compound 16 appeared to be
even more stable and retained 80% of its antagonistic activity
after a 24 hr incubation in mouse serum. In addition, the three
compounds retained 60%–70% of their efficacy after a 72 hr
incubation in medium conditioned by PC3 prostate cancer cells.
This is in contrast with the lower stability observed for the KYL-
PYWPVLSSL peptide (Lamberto et al., 2012), which in our assay
showed half-lives of 0.6 and 7 hr in mouse serum and in cell
culture medium, respectively (Figure S7). Taken together, these
results suggest that the compounds we have identified by using
the HTS by NMR approach represent a worthy starting point for
the development of EphA4 antagonists with markedly improved
drug-like properties over existing peptides and small molecules.
Conclusions
To our knowledge, we reported on a new fragment screening
strategy, HTS by NMR. We demonstrated the feasibility of this30 Chemistry & Biology 20, 19–33, January 24, 2013 ª2013 Elseviermethod by applying it first to a test case and subsequently to
a de novo ligand-discovery program against the EphA4 LBD.
An overall screening procedure was first established and tested
against the EphA4 LBD, resulting in compound 22. This
compound exhibits significant binding affinity and selectivity
for the targeted ligand binding domain of EphA4, providing
convincing proof-of-concept data that support the feasibility of
the approach and the establishment of effective screening and
optimization protocols. Our data clearly demonstrate the effec-
tiveness and usefulness of our strategy for the rapid identifica-
tion and optimization of compounds interacting with a target
protein. Currently, we are evolving the approach using nonpep-
tide libraries arranged in the same positional scanning format
(Houghten et al., 2008; Judkowski et al., 2011). Based on the
data reported, we believe the approach may find its utility espe-
cially in the identification of inhibitors of PPIs, allosteric inhibitors,
and their binding sites, and for establishing the overall druggabil-
ity of targets.
SIGNIFICANCE
The challenge of FBLD approaches is that the evolution of
initial weakly interacting fragments into more mature com-
pounds with low micromolar affinity (usually the starting
point for subsequent hit-to-lead optimizations) is not trivial
and often involves attaining properly linked compound frag-
ments. Approaches such as the SAR by NMR (Shuker et al.,
1996) may also require structural studies and several itera-
tions. Our idea is to combine the robustness of protein
NMR spectroscopy as the detection method with the
basic principles of combinatorial chemistry to enable the
screening of large libraries of preassembled fragments
(>105 compounds) on a common backbone. Hence, we
term the approach HTS by NMR. The approach seems
particularly suited to target larger protein-protein interac-
tion surfaces. We indeed demonstrated the feasibility of
HTS by NMR using a well-studied target, the baculovirus
IAP repeat 3 (BIR3) domain, and further, we used the
approach to identify novel (to our knowledge) and potent
compounds that target the ligand binding domain of the
EphA4 receptor.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification
The human EphA4 LBD (residues 29–209) was prepared as described
previously (Qin et al., 2008). Briefly, the pET32a´ vector containing the EphA4
LBD cDNA fragment (kindly provided by Dr. Song) was transformed into
Escherichia coli Rosetta-gami (DE3) cells (Novagen). The transformed cells
were then transferred into L-Broth medium and were grown at 37C. A total
of 0.4 mM isopropyl 1-thio-D-galactopyranoside was added into the growing
cells when optical density reached 0.7 and continued to grow at 20C
overnight. The overexpressed protein was purified using Ni2+ affinity chroma-
tography. The generation of the isotope-labeled proteins for NMR studies
followed a similar procedure except that the bacteria were grown in M9
medium with the addition of (15NH4)2SO4 for
15N labeling.
Library and Peptide Synthesis
The positional scanning libraries were prepared at the Torrey Pines Institute for
Molecular Studies as described previously (Pinilla et al., 1992, 1994) using the
simultaneous multipeptide synthesis method (Pinilla et al., 1994). All librariesLtd All rights reserved
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one of the component in a defined position and X represents a mixture of all
the components. The hexapeptide positional scanning library (TPI 1069) is
made up of all the combinations of 19 natural amino acids with the exception
of cysteine; the tetrapeptide positional scanning library (TPI 367/378) contains
52 components, at each of the four diversity positions, composed of L (16), D
(14), and unnatural (22) amino acids; the tripeptide positional scanning library
(TPI 1455) contains 58 components, at each of the three diversity positions,
composed of L (17), D (16), and unnatural (25) amino acids (Table S2). Each
mixture in the hexapeptide, tetrapeptide, and tripeptide libraries is composed
of 2.5 million, 140,680, and 3,364 compounds, respectively. All mixtures of the
libraries are N-terminal free and C-terminal amide.
Fluorescence Polarization Assays
An EphA4 KYL peptide (KYLPYWPVLSSL) (Murai et al., 2003) was labeled
at the N terminus with fluorescein isothiocyanate (FITC) and purified by high-
performance liquid chromatography. For competitive binding assays, 1 ml of
200 mM EphA4 LBD was preincubated with the tested compounds at various
concentrations in 98 ml PBS (pH = 7.2) in 96-well black plates at room temper-
ature for 10 min, and then 1 ml of 500 mM FITC labeled EphA4 peptide was
added to produce a final volume of 100 ml. The KYL and DMSOwere incubated
in each assay as positive and negative controls, respectively. After 30 min of
incubation at room temperature, the polarization values in millipolarization
units were measured at excitation/emission wavelengths of 480/535 nm with
a multilabel plate reader (PerkinElmer, Waltham, MA, USA). IC50 was deter-
mined by fitting the experimental data to a Sigmoidal dose-response (variable
slope) nonlinear regression model (GraphPad Prism version 5.01 for Windows,
GraphPad Software, San Diego, CA, USA).
NMR Spectroscopy
NMRspectra were acquired on 600 and 700MHzBruker Avance spectrometer
equipped with either TCI probe and z-shielded gradient coils or a TCI
cryoprobe. All NMR data were processed and analyzed using TOPSPIN2.1
(Bruker Biospin, Billerica, MA, USA) and SPARKY3.1 (University of California,
San Francisco, CA, USA). 2D-[15N, 1H]-HSQC experiments were acquired
using 32 scans with 2,048 and 128 complex data points in the 1H and 15N
dimensions at 300 K. Compound binding was detected at 27C by comparing
the 2D-[15N, 1H]-HSQC spectra of 50 mM EphA4 LBD in the absence and
presence of compounds at mole ratio 2:1, respectively. The chemical shift
changes were calculated using the following Equation 1 (Farmer et al., 1996):
Dd=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
D1H
2
+

0:17  D15N2
q
: (1)
Dissociation equilibrium constants (Kd) of compounds against EphA4 were
determined by monitoring the protein chemical shift perturbations as function
of compound concentration. For instance, equivalent amounts of compounds
were added to a 50 mM sample of EphA4 to yield 1:1, 2:1 stoichiometries of
protein/ligand concentration. Titration analysis was done by fitting chemical
shift data into a quadratic equation as described in the following Equation 2
(Pellecchia, 2005; Smet et al., 2005):
Ddobs =Ddmax

Kd + ½L0 + ½P0

ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Kd + ½L0 + ½P0
24½P0½L0
q
2½P0
; (2)
where Dobs is the observed chemical shift perturbation value at each titration
point, Dmax is the maximum chemical shift perturbation value of the fully com-
plexed protein, and [L]0 and [P]0 are the total concentrations of compound and
protein.
Binding Constant Determination by ITC
Isothermal titration calorimetry was performed on a VP-ITC calorimeter from
Microcal (Northampton, MA, USA). When indicated, measurements were
performed in a reverse way—i.e., the protein was titrated into the compound
solution. A total of 8 ml EphA4 solution (1.65 mM) was injected into the cell
containing 165 mM compound per injection. In each experiment, 37 injections
were made. All titrations were performed at 25C in PBS buffer supplemented
with 10%DMSO. Experimental data were analyzed using Microcal Origin soft-
ware provided by the ITC manufacturer (Microcal).Chemistry & Biology 20,ELISAs
Protein A-coated wells (Pierce Biotechnology, Rockford, IL, USA) were used to
immobilize Eph receptor Fc fusion proteins (R&D Systems, Minneapolis, MN,
USA) incubated at 1 mg/ml in TBST (50 mM Tris-HCl [pH 7.5], 150 mM NaCl,
0.01% Tween-20). The compounds were added to the plates for 2 hr before
adding culture supernatants from transfected 293HEK cells containing ephrins
fused to alkaline phosphatase (ephrin-A5 AP, 0.005 nM final concentration;
ephrin-B2 AP, 0.01 nM final concentration) (Koolpe et al., 2002; Noberini
et al., 2008). The culture supernatants were diluted in TBST and incubated
for an additional 20 min in the presence or in the absence of compounds.
The amount of bound AP fusion protein was quantified using pNPP as the
substrate. Ephrin-AP concentrations were calculated from AP activity (Cullen,
2000; Flanagan et al., 2000). Unless otherwise specified, all the binding and
washing steps were performed in TBST. IC50 values were calculated using
nonlinear regression and the programGRAPHPAD (PRISM, La Jolla, CA, USA).
Measurement of Compound Stability in Mouse Serum and Cell
Culture Medium
PC3 prostate cancer cells were grown in RPMI 1640 medium (Mediatech,
Herndon, VA, USA) with 10% FBS (Hyclone, Logan, UT, USA), penicillin, and
streptomycin. The compoundswere added tomouse serum or culturemedium
conditioned by PC3 cells and incubated at 37C for different times. Serum and
culture medium were then diluted 1:20 (corresponding to a final concentration
150 mM) in ELISA wells and incubated for 2 hr in the presence of 0.005 nM
ephrin-A5 AP. Inhibition of EphA4-ephrin-A5 binding was measured as
described above. Absorbance from wells coated with Fc and incubated with
ephrin-A5 AP and serum or culture medium was subtracted as the back-
ground. Absorbance obtained from wells incubated with mouse serum or
conditioned medium not containing any compound was used to determine
the 0% inhibition level (efficacy = 0), and absorbance obtained in the presence
of the compounds mixed with serum or medium immediately before adding
them to the ELISA wells was used for normalization (efficacy = 1).
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